Under this new agreement, the parties will leverage AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly’s drug candidate programs and ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Announced on February 10, Eli Lilly is expanding its collaboration with AdvanCell to advance targeted alpha therapies for cancer treatment. By using AdvanCell’s Pb-212 production technology and ...

Prior to the Eli Lilly deal, POINT Biopharma had partnered with AdvanCell to support the clinical development and commercialisation of Pb-212-based radioligands. Other companies, including Orano ...

Dealmaking in the Asia Pacific (APAC) region took off this week, with the latest showcasing Genome & Co.’s licensing deal with Ellipses Pharma Ltd. for GENA-104, a phase I-ready immuno-oncology asset, ...

BRISBANE, Australia & INDIANAPOLIS, February 10, 2025--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an ...

BRISBANE, Australia & INDIANAPOLIS — AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its ...